Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Phase 2TerminatedNCT00057447

InterMune24 enrolled

Overview

Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non-Hodgkin's Lymphoma

Interventions

Interferon Gamma-1bDRUG

100 or 200 mcg, SQ, 3x per week

RituximabDRUG

375 mg per square meters, IV, 1x per week

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

* Relapsed or progressive low-grade/follicular NHL who are candidates for rituximab therapy * Patients who were on other therapy including CHOP or radiation * Previous therapy must have concluded 30 days prior to enrollment * Demonstrable CD20-positive tumor population in lymph nodes or bone marrow

Locations (1)

Intermune Inc

Brisbane, California, United States

Outcomes

Primary Outcomes

time to complete response (disappearance of all detectable clinical and radiographic evidenc of disease, and regression of lymph nodes)

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.